Kapetanovic et al identified risk factors for an infusion reaction to infliximab. These can help to identify patients who are more likely to experience this complication. The authors are from Lund University in Sweden.
Patient selection: rheumatoid arthritis (RA)
Key risk factors for an infusion reaction to infliximab:
(1) positive antinuclear antibody (ANA) at baseline
(2) being treated with infliximab without methotrexate (monotherapy)
Additional risk factors:
(1) lower age at disease onset
(2) longer disease duration
No predictors were found for infusion reactions in patients with spondyloarthropathies.
To read more or access our algorithms and calculators, please log in or register.
